RxDoctor Payments Data

Safal Shetty, MD

Pulmonary Disease · Douglasville, GANPI 1013192384

Payments from drug & device makers

$11,210in general payments, 2019–2025

Across 473 payments — averaging $23.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inspire Medical Systems, Inc.$2K
  • GSK$2K
  • Grifols USA, LLC$818
  • Boehringer Ingelheim$754
  • Regeneron Healthcare Solutions, Inc.$732
  • AstraZeneca$683
  • plus $4K from 39 others

What the payments were for

  • Travel & lodging$9318%
  • Food & beverage$9,82288%
  • Education$4584%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,210 in reported general payments places this provider in the 70th percentile of 365 pulmonary disease providers in Georgia.

See all pulmonary disease providers in Georgia

Medicare billing

Part B allowed, 2024
$132,784
Medicare patients
471
Services billed
1,666

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter159$134,989
Prolastin CAlpha-1-Proteinase Inhibitor12$127,742
Breo ElliptaFluticasone/Vilanterol64$42,125
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr74$35,097
Advair HfaFluticasone Propion/Salmeterol59$33,262
Breztri AerosphereBudesonide/Glycopyr/Formoterol39$24,300
Stiolto RespimatTiotropium Br/Olodaterol Hcl37$19,249
Spiriva RespimatTiotropium Bromide13$14,208
SymbicortBudesonide/Formoterol Fumarate36$11,555
EliquisApixaban15$11,103
Albuterol Sulfate HfaAlbuterol Sulfate241$6,775
Wixela InhubFluticasone Propion/Salmeterol45$6,283
Fluticasone-SalmeterolFluticasone Propion/Salmeterol37$4,722
BreynaBudesonide/Formoterol Fumarate13$3,238
Ventolin HfaAlbuterol Sulfate25$1,349

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$1,870$212,211297 claims
Grifols USA, LLCProlastin C$818$127,74212 claims
AstraZenecaBreztri Aerosphere, Symbicort$683$35,85675 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat$754$33,45750 claims
PfizerEliquis$34$11,10315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 365 pulmonary disease providers in Georgia.

Other pulmonary disease in Douglasville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →